Admissions to paediatric intensive care units (PICU) with refractory convulsive status epilepticus (RCSE): A two-year multi-centre study

被引:14
|
作者
Tully, I. [1 ,2 ]
Draper, E. S. [3 ]
Lamming, C. R. [3 ]
Mattison, D. [4 ]
Thomas, C. [1 ]
Martland, T. [4 ]
Appleton, R. [5 ]
机构
[1] Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England
[2] Univ Wales Hosp, Inst Med Genet, Cardiff CF14, S Glam, Wales
[3] Univ Leicester, Coll Med Biol Sci & Psychol, Dept Hlth Sci, Leicester LE1 7RH, Leics, England
[4] Royal Manchester Childrens Hosp, Dept Neurol, Manchester M13 9WL, Lancs, England
[5] Alder Hey Childrens Hosp, Dept Neurol, Liverpool L12 2AP, Merseyside, England
来源
关键词
Refractory; Status epilepticus; Children; Intensive care; Thiopentone; Midazolam; NONCONVULSIVE STATUS EPILEPTICUS; INTRAVENOUS VALPROATE; CONTINUOUS MIDAZOLAM; DIAZEPAM INFUSION; SODIUM VALPROATE; LOW MORBIDITY; CHILDREN; EFFICACY; SEIZURES; MORTALITY;
D O I
10.1016/j.seizure.2015.04.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aims: To obtain national epidemiological data on the aetiology, management and outcome of refractory convulsive status epilepticus (RCSE) in children. Methods: Data on children admitted with RCSE between 01.01.2008 and 31.12.2009, to eight paediatric intensive care units (PICUs) were retrospectively collected using a standard proforma designed with and co-ordinated by PICANet. Results: Data were collected on 245 (male, 179) patients aged between <1 month and 16.5 years (median 2.8 years, IQR 1-7.43 years), of which: One hundred and fifty-one patients (male, 89) aged between <1 month and 16.5 years (median 2.3 years, IQR 1-7.17 years) met the study criteria for a diagnosis of RCSE. Causes included acute symptomatic (15.2%), remote symptomatic (29.0%), epilepsy-related (10.6%), progressive encephalopathy (10.6%) febrile seizures (18.2%); no cause was identified in 16.4%. First line treatments included lorazepam (118 patients, 78.1%), diazepam (72,47.7%) and midazolam (37, 24.5%). Second-line treatments included phenytoin (125 patients, 82.8%) and phenobarbital (seven patients, 4.6%). Third-line treatments included a thiopentone bolus (99 patients, 65.6%), thiopentone infusion (20, 13.2%) midazolam infusion (56, 37.1%) phenobarbital (18, 11.9%), propofol (6, 4.0%) and clonazepam (2, 1.3%). Deviation from the national advanced paediatric life support (APLS) protocol was noted in approximately one quarter of all patients. Six patients died (4.0%). Seventeen patients (11.3%) developed a new neurological deficit on discharge from PICU, of which eight (5.3%) continued to show this deficit at a 30-day follow-up and 12 patients (7.9%) developed de novo epilepsy. Conclusions: Thiopentone was the most commonly used anticonvulsant to treat RCSE on admission to PICU. Mortality was low and approximately 1 in 25 showed a new neurological deficit at the 30-day follow-up. (C) 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:153 / 161
页数:9
相关论文
共 26 条
  • [1] CHILDREN WITH REFRACTORY CONVULSIVE STATUS EPILEPTICUS ADMITTED TO INTENSIVE CARE IN ENGLAND AND WALES: A TWO-YEAR NATIONAL EPIDEMIOLOGICAL STUDY
    Tully, I
    Draper, E.
    Lamming, C.
    Matthison, D.
    Thomas, C.
    Appleton, R.
    Martland, T.
    [J]. EPILEPSIA, 2013, 54 : 116 - 116
  • [2] Convulsive status epilepticus in a quaternary hospital paediatric intensive care unit (PICU) in South Africa: An 8 year review
    Reddy, Yavini
    Balakrishna, Yusentha
    Mubaiwa, Lawrence
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2017, 51 : 55 - 60
  • [3] Aetiology, course and outcome of children admitted to paediatric intensive care with convulsive status epilepticus: A retrospective 5-year review
    Hussain, Nahin
    Appleton, Richard
    Thorburn, Kent
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2007, 16 (04): : 305 - 312
  • [4] Exogenous acquisition of Pseudomonas aeruginosa in intensive care units: a prospective multi-centre study (DYNAPYO study)
    Coppry, M.
    Leroyer, C.
    Saly, M.
    Venier, A-G
    Slekovec, C.
    Bertrand, X.
    Parer, S.
    Alfandari, S.
    Cambau, E.
    Megarbane, B.
    Lawrence, C.
    Clair, B.
    Lepape, A.
    Cassier, P.
    Trivier, D.
    Boyer, A.
    Boulestreau, H.
    Asselineau, J.
    Dubois, V
    Thiebaut, R.
    Rogues, A-M
    [J]. JOURNAL OF HOSPITAL INFECTION, 2020, 104 (01) : 40 - 45
  • [6] Comparing the Waterlow and Jackson/Cubbin pressure injury risk scales in intensive care units: A multi-centre study
    Yang, Qiuxia
    Yang, Zhuang
    Lv, Lin
    Zhang, Hongyan
    Tao, Hongxia
    Pei, Juhong
    Ma, Yuxia
    Han, Lin
    [J]. INTERNATIONAL WOUND JOURNAL, 2024, 21 (02)
  • [7] Device associated infections in intensive care units of a tertiary care hospital-a two-year analytical study
    Ganesan, Vithiya
    Sundaramurthy, Raja
    Charles, Jhansi
    Mayil, Maragathavalli
    Devi, S.
    Muthumariammal, D.
    Ananthi, D.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 58 : 65 - 65
  • [8] Mortality and recovery from refractory status epilepticus in the intensive care unit: A 7-year observational study
    Sutter, Raoul
    Marsch, Stephan
    Fuhr, Peter
    Rueegg, Stephan
    [J]. EPILEPSIA, 2013, 54 (03) : 502 - 511
  • [9] Aetiology, course and outcome of children admitted to paediatric intensive care with convulsive status epilepticus: A five-year experience: 'Zero mortality and low morbidity'
    Hussain, N.
    Appleton, R.
    Thorburn, K.
    [J]. EPILEPSIA, 2006, 47 : 6 - 6
  • [10] Predictors of hospital and one-year mortality in intensive care patients with refractory status epilepticus: a populationbased study
    Kantanen, Anne-Mari
    Kalviainen, Reetta
    Parviainen, Ilkka
    Ala-Peijari, Marika
    Backlund, Tom
    Koskenkari, Juha
    Laitio, Ruut
    Reinikainen, Matti
    [J]. CRITICAL CARE, 2017, 21